A large-scale retrospective analysis including 1,136,016 patients that identified only minimal prognostic differences between HER2-low and HER2-0 breast cancer appears to show that HER2-low-positive tumors are not a new biological class [27]. This evidence concerns the gene ERBB2 and breast cancer.